Jefferies Financial Group Issues Pessimistic Forecast for Hims & Hers Health (NYSE:HIMS) Stock Price

Hims & Hers Health (NYSE:HIMS) had its price target lowered by stock analysts at Jefferies Financial Group from $31.00 to $24.00 in a research report issued on Tuesday, Benzinga reports. The firm currently has a “hold” rating on the stock. Jefferies Financial Group‘s price objective would indicate a potential upside of 26.12% from the stock’s current price.

Other equities research analysts have also recently issued research reports about the company. Weiss Ratings reissued a “sell (d)” rating on shares of Hims & Hers Health in a report on Wednesday, November 4th. Truist Financial increased their price target on Hims & Hers Health from $27.00 to $32.00 and gave the company a “hold” rating in a research note on Monday, August 24th. TD Cowen lifted their price target on Hims & Hers Health from $25.00 to $30.00 and gave the company a “hold” rating in a research report on Tuesday, August 11th. Morgan Stanley dropped their price objective on Hims & Hers Health from $28.00 to $25.00 and set an “equal weight” rating on the stock in a research note on Tuesday. Finally, JPMorgan Chase & Co. started coverage on Hims & Hers Health in a report on Friday, September 11th. They issued a “neutral” rating and a $32.00 price objective for the company. Three research analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Hims & Hers Health presently has an average rating of “Hold” and an average target price of $31.53.

Hims & Hers Health Price Performance

Shares of HIMS stock traded down $3.91 during midday trading on Tuesday, reaching $19.03. 57,894,076 shares of the company were exchanged, compared to its average volume of 22,403,338. The company’s 50 day moving average price is $28.31 and its two-hundred day moving average price is $26.91. The company has a market cap of $4.44 billion, a P/E ratio of -30.21 and a beta of 2.53. Hims & Hers Health has a 12 month low of $13.74 and a 12 month high of $41.28. The company has a debt-to-equity ratio of 4.21, a quick ratio of 0.87 and a current ratio of 0.93.

Hims & Hers Health (NYSE:HIMS) last posted its quarterly earnings data on Monday, August 10th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.05) by ($0.32). Hims & Hers Health had a negative net margin of 5.51% and a negative return on equity of 6.51%. The company had revenue of $753.21 million during the quarter, compared to the consensus estimate of $698.90 million. During the same quarter last year, the business earned $0.17 earnings per share. The company’s revenue was up 38.2% on a year-over-year basis. On average, sell-side analysts expect that Hims & Hers Health will post -0.16 earnings per share for the current year.

Insider Activity at Hims & Hers Health

In related news, insider Soleil Boughton sold 3,462 shares of the stock in a transaction that occurred on Wednesday, October 28th. The shares were sold at an average price of $27.60, for a total transaction of $95,551.20. Following the completion of the sale, the insider directly owned 293,886 shares of the company’s stock, valued at $8,111,253.60. This represents a 1.16% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Michael Chi sold 14,027 shares of the firm’s stock in a transaction that occurred on Tuesday, September 15th. The stock was sold at an average price of $28.39, for a total transaction of $398,226.53. Following the sale, the chief operating officer owned 456,660 shares of the company’s stock, valued at $12,964,577.40. The trade was a 2.98% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 133,905 shares of company stock valued at $3,826,977 over the last ninety days. Insiders own 11.76% of the company’s stock.

Hedge Funds Weigh In On Hims & Hers Health

Hedge funds have recently modified their holdings of the stock. Bank of America Corp DE grew its holdings in shares of Hims & Hers Health by 194.4% during the first quarter. Bank of America Corp DE now owns 4,357,672 shares of the company’s stock valued at $90,465,000 after buying an additional 2,877,550 shares in the last quarter. Bank of New York Mellon Corp acquired a new position in Hims & Hers Health during the second quarter valued at $46,220,000. Bienville Capital Management LLC acquired a new position in Hims & Hers Health during the second quarter valued at $27,242,000. Principal Financial Group Inc. lifted its stake in Hims & Hers Health by 97.3% in the 1st quarter. Principal Financial Group Inc. now owns 1,282,266 shares of the company’s stock worth $26,620,000 after acquiring an additional 632,282 shares in the last quarter. Finally, Southpoint Capital Advisors LP purchased a new stake in Hims & Hers Health in the 1st quarter worth about $10,380,000. 63.52% of the stock is currently owned by institutional investors and hedge funds.

Hims & Hers Health News Summary

Here are the key news stories impacting Hims & Hers Health this week:

• Positive Sentiment: Q3 revenue rose 49% year over year to $890.4 million, showing continued business growth, although it came in just below analysts’ expectations. Article: Hims & Hers: 3 Key Takeaways for Long-Term Investors
• Neutral Sentiment: The company plans to offer an unapproved peptide after U.S. restrictions eased. The move could create a growth opportunity, but its commercial and regulatory impact is uncertain. Article: Hims & Hers to offer an unapproved peptide after US eases curbs
• Negative Sentiment: Q3 earnings per share were $0.03, below estimates of $0.06–$0.07. Gross margin also contracted sharply, while subscribers fell by 100,000 sequentially to 2.8 million—raising questions about growth quality and costs. Article: Hims & Hers: Why I’m Not Buying Back Yet
• Negative Sentiment: Management lowered its 2026 adjusted EBITDA outlook to $257 million–$277 million, from $300 million–$375 million previously. Its Q4 revenue forecast of $875 million–$895 million is also well below the roughly $956 million analyst consensus; the full-year revenue range is $3.1 billion–$3.2 billion. Article: Hims & Hers narrows 2026 revenue forecast as margins contract
• Negative Sentiment: Analysts cut price targets: Morgan Stanley lowered its target to $25 and Needham to $32, though Needham maintained a Buy rating. Article: Hims & Hers Stock Feels a Pinch Tuesday

Hims & Hers Health Company Profile

Hims & Hers Health, Inc. operates a consumer-focused telehealth platform that connects patients with licensed healthcare providers and offers access to treatments and wellness products. Its services include online consultations, prescription care and over-the-counter products. The company serves a range of health needs, including hair loss, sexual health, skin care, mental health and weight management. Its platform also offers primary care and other services, with offerings varying by location and individual eligibility.